Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | PDXK | O00764 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13909713 | 0.81 | LMNA (0.36) | LMNAKDM4E | |
| SCHEMBL9409112 | 0.79 | DHFR (0.44) | LMNA | |
| SCHEMBL7560692 | 0.78 | — | — | |
| SCHEMBL2493947 | 0.77 | LMNA (0.39) | LMNAPDXKKDM4EALDH1A1HPGD | |
| SCHEMBL479344 | 0.75 | LMNA (0.61) | LMNAKDM4EALDH1A1 | |
| SCHEMBL11284274 | 0.75 | LMNA (0.66) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL28840489 | 0.74 | PLAU (0.38) | — | |
| Hydrochloric Acid SCHEMBL6520994 | 0.73 | LMNA (0.59) | LMNAKDM4EALDH1A1 | |
| SCHEMBL8445448 | 0.73 | LMNA (0.59) | LMNAKDM4EALDH1A1 | |
| SCHEMBL5726466 | 0.73 | FEN1 (0.33) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7893259-B2 | Pyrido-pyrimidine derivatives, preparation thereof, and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2011-02-22 | — | — | US | disclosed |
| US-20090233923-A1 | PYRIDO-PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-09-17 | — | — | US | disclosed |
| US-7544677-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-7504406-B2 | Derivatives of pyrido[2,3-d]pyrimidine, the preparation thereof, and the therapeutic application of the same | SANOFI-AVENTIS (FR) | 2009-03-17 | — | — | US | disclosed |
| US-20080176874-A1 | Derivatives of Pyrido[2,3-d]pyrimidine, the Preparation Thereof, and the Therapeutic Application of the Same | SANOFI-AVENTIS (FR) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176874-A1 | Derivatives of Pyrido[2,3-d]pyrimidine, the Preparation Thereof, and the Therapeutic Application of the Same | DPYD, TYMP, TYMS | LMNA 2379/4885PDXK 12/4885KDM4E 2063/4885 |
| US-20090233923-A1 | PYRIDO-PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | DPYD, PNPO, TYMP | LMNA 2577/4885PDXK 4/4885KDM4E 3372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.